London, May 2, 2026, 23:01 (BST)
- Haleon PLC reported 8.879 billion ordinary shares with voting rights as of April 30, giving investors the latest base for UK disclosure calculations.
- The update lands during a £500 million 2026 buyback programme, with about 36% completed by the first-quarter statement.
- The capital return comes as investors weigh slower first-quarter sales growth, rising freight costs and a hoped-for North America rebound.
Haleon PLC said its total ordinary shares with voting rights stood at 8,879,691,798 as of April 30, a fresh capital update that gives shareholders the denominator for deciding whether they must disclose changes in their stakes.
The filing is small in tone, but not irrelevant. Haleon, the London-listed owner of Sensodyne, Panadol and Advil, is using buybacks to tighten its capital base while trying to show that first-quarter softness was seasonal, not structural. Treasury shares — stock the company holds itself and which does not carry voting rights — stood at 12,240,797, the filing showed.
The new voting-rights figure was about 11.4 million shares below the number cited for the April 24 annual meeting record date, when Haleon reported 8,891,124,301 total voting rights. Shareholders at that meeting also backed a resolution allowing the company to purchase its own shares.
Haleon has allocated £500 million to share buybacks in 2026 and said in its first-quarter trading statement that roughly 36% had been completed. Buybacks reduce the share count when stock is cancelled, or can move shares into treasury for later use.
The company’s latest operational update was less tidy. Haleon reported first-quarter revenue of £2.86 billion and organic revenue growth — sales growth excluding currency, acquisitions, divestments and some supply agreements — of 2.2%, with price up 2.4% and volume down 0.2%.
That matters because Haleon is still asking investors to believe growth will accelerate. The company reiterated its 2026 outlook for 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency, meaning profit growth measured before exchange-rate effects.
Chief Executive Brian McNamara said Haleon saw “North America returning to growth” and expected “growth to accelerate” over the rest of the year, while noting global geopolitical and macroeconomic uncertainty. North America, its largest market, posted 1.0% organic growth in the quarter, helped by Sensodyne and parodontax. Haleon Corporate
The pressure point is broader than Haleon. Reuters reported that consumer companies including Procter & Gamble and Reckitt have faced higher energy and freight costs, while soft demand for cold and flu products also weighed on Reckitt’s quarterly performance. Haleon owns Theraflu and Robitussin, leaving it exposed when the cold and flu season is weak.
Finance chief Dawn Allen said Haleon had started to see “surcharges on freight” and would “expect that to increase,” though the company has fixed-price contracts and hedges in most areas through year-end. Haleon may also adjust pricing where it can, McNamara told analysts, according to Reuters. Reuters
The risk is that buybacks do not solve a demand problem. Haleon said a weak cold and flu season cut about 130 basis points from first-quarter organic growth, while Reuters reported Middle East consumer spending was down by a low-double-digit percentage in a region that accounts for about 5% of revenue.
Quilter analyst Chris Beckett put the market concern plainly, telling Reuters that Haleon “needs more than the toothpaste business to start performing.” Oral Health grew 8.3% organically in the quarter, far ahead of Respiratory Health, which fell 3.4%. Reuters
Haleon shares were last quoted at 344.10 pence in London on May 1, up 1.21% on the day, after falling earlier in the week when the company flagged cost pressure and slower first-quarter sales growth.
